Introduction
HIV-positive (HIVþ) people are living longer with the use of antiretroviral therapy (ART) [1, 2] but are now experiencing an increasing burden of chronic diseases, including coronary artery disease (CAD) [1] . Although traditional cardiovascular risk factors are more prevalent in HIVþ populations, they do not adequately account for the increased cardiovascular risk observed in HIVþ individuals [2] . Thus, the underlying mechanisms that predispose HIVþ patients to accelerate atherosclerosis and clinical events are important to identify but remain poorly characterized and understood.
Coronary endothelial function (CEF) is both an early, causal factor that contributes critically to the development of coronary atherosclerosis and a predictor of later progression to clinical events in the general population [3] . Depressed CEF responds favorably to risk factor modification, and thus CEF is often considered a barometer of vascular health [4] . Healthy endothelial cells release nitric oxide (NO) during stress, resulting in vasodilatation and increased coronary blood flow (CBF) but endothelial dysfunction is associated with an impaired vasoactive response [5] . CEF was previously only assessed invasively in the catheterization laboratory by measuring changes in coronary diameter and flow in response to endothelial-dependent stressors [6] . The invasive nature of cardiac catheterization precluded CEF studies in healthy, low-risk individuals before the development of CAD, and in stable CAD patients. Although systemic endothelial dysfunction was reported in HIVþ people [7] , peripheral artery endothelial function correlates only modestly with CEF [8] , and the latter is more closely related to underlying CAD [5, 9, 10] .
It is not known whether CEF is depressed in HIVþ populations, but CEF measures promise important biologic insights into both early and later coronary consequences of contemporary HIV infection. Recently, noninvasive measures of CEF were developed using MRI to detect changes in coronary artery area and blood flow in response to isometric handgrip exercise (IHE), an endothelial-dependent stressor [9, 10] . Those MRI-IHE detected coronary responses were shown to be NOdependent, reproducible, and thus indicative of CEF [9, 10] . We exploit these new noninvasive CEF techniques here to test the hypothesis that CEF is impaired early in HIVþ populations, even before the development of CAD, as compared with age-matched and risk factormatched healthy HIV-negative (HIVÀ) patients. To probe the later vascular consequences of HIV, we determined whether CEF is further worsened in HIVþ patients with known CAD as compared with stable CAD patients without HIV infection.
As chronic inflammation plays an important role in the pathogenesis of atherosclerosis in both the general population [11] and in HIV-infected patients, we also determined whether the extent of any impairment in CEF in HIVþ people is related to the circulating levels of the inflammatory biomarkers, high-sensitivity C-reactive protein (hsCRP), and IL-6 [12] .
Methods

Patients
All participants provided written informed consent to a protocol approved by the Johns Hopkins Medicine Institutional Review Board. Patients had no contraindications to MRI and patients were recruited from outpatient clinics at the Johns Hopkins Hospital. Four group of patients were recruited: first, healthy patients without HIV and without CAD, defined as 50 years or younger without a history of CAD, diabetes or more than one CAD risk factor, or over age 50 years with an Agatston et al. [13] coronary artery calcium (CAC) score of 0 (HIVÀCADÀ, n ¼ 36) within the last 5 years; second, patients with a diagnosis of HIV without CAD defined as no significant cardiac history and a CAC score of 0 (HIVþCAD, n ¼ 18). A contrast-enhanced computed tomography angiogram was also performed in the majority of the HIVþCADÀ patients (15/18; 83%) and demonstrated 30% or less coronary irregularities; third, patients with known CAD (defined as presence of between 30 and 70% luminal stenosis, on prior coronary radiograph angiography) and without HIV infection (HIVÀCADþ, n ¼ 41); and fourth, HIVþ patients with known CAD (HIVþCADþ, n ¼ 17). The coronary disease in both the HIVþ and HIVÀ groups was stable, and the patients were receiving medical management. The HIVþ participants on ART were on stable therapy for at least 1 year.
MRI study protocol A commercial 3.0 Tesla (T) whole-body magnetic resonance (MR) scanner (Achieva; Philips, Best, The Netherlands) with a 32-element cardiac coil for signal reception was used. Detailed MR parameters were previously reported [9, 10, 14] . Participants underwent MRI in the morning in the fasting state (>8 h) before the administration of any prescribed vasoactive medications. Images were taken perpendicular to a segment of a native coronary artery that had not undergone prior intervention or, if not, did not have a significant stenosis by invasive angiography. To ensure that slice orientation was perpendicular to the coronary artery, double oblique scout scanning was performed [15] . Alternating anatomical and velocity-encoded images were collected at baseline and during 4-7 min of continuous IHE using an MRI-compatible dynamometer (Stoelting, Wood Dale, Illinois, USA) [16] at 30% of maximum grip strength and while being directed by a research nurse. The imaging plane for the endothelial function measurements was localized to a proximal or mid-coronary arterial segment that was straight over a distance of approximately 20 mm. In cases, where two coronary arteries per participant and/ or different segments of the same vessel could be imaged, the results for each were quantified and averaged. Heart rate (HR), and blood pressure were measured throughout using a noninvasive and MRI-compatible ECG and calf BP monitor (Invivo; Precess, Orlando, Florida, USA). The rate pressure product (RPP) was calculated as SBP Â HR. The total duration of each MRI exam was $50 min.
Image analysis
Baseline and IHE-stress images for coronary crosssectional area (CSA) and velocity-encoded images for flow calculation were analyzed as previously described [9, 14] . Coronary flow velocity was measured in cm/s and CBF was calculated as previously described [10, 14, 17] . Segments with poor image quality (blurring due to artifact/patient motion) on either the baseline or stress exams were excluded from analysis. Both per segment and per patient analyses were performed. MRI interpretation was performed by two independent readers who were blinded to clinical and laboratory information at the time of analysis but not to HIV status.
Laboratory measurements
Venous blood samples were collected on the day of the study after an overnight fast to determine the concentration of hsCRP and IL-6 in most patients (HIVÀ/ CADÀ, n ¼ 18; HIVþ/CADÀ, n ¼ 16; HIVÀ/CADþ, n ¼ 35; HIVþ/CADþ, n ¼ 12). The hsCRP sample was collected in a gel tube and measured using the turbidimetry method by the Johns Hopkins Hospital main chemistry lab. IL-6 was measured with ELISA by Quest laboratory. A fasting lipid panel, CD4
þ cell count and HIV and hepatitis C virus (HCV) RNA measurements were obtained on the day of the study or were available in the electronic medical records within the last 6 months.
Statistical analysis
Statistical analysis was performed with SAS (SAS 9.4; SAS Institute, Cary, North Carolina, USA). Data are expressed as mean AE SEM. The data were tested for normality using the Shapiro-Wilk test. To compare between-group differences in demographic and clinical characteristics, lipid profiles, and other factors, nonparametric analysis of variance was used for continuous variables, and the chisquare test was employed for categorical variables. Multiple linear regression model was used to examine if HIV-serostatus was independently associated with CEF. The initial multivariate regression model included all covariates. The importance of each variable included in the multivariate model was evaluated with an examination of the Wald statistic for each variable in the model, and a comparison of each estimated regression coefficient in the multivariate model with the regression coefficient from the corresponding univariate model. Those variables that ceased to make significant contributions to the models based on these two criteria were deleted in a stagewise manner, and a new model was refitted. This process of eliminating, refitting, and verifying continued until all of the variables included were statistically significant, yielding a final model. Linear regression analysis was performed to assess correlation between inflammatory markers (hsCRP and IL-6) and each CEF parameter: area and flow change with IHE from baseline. As laboratory and imaging measurements may include influential data, which may contain important information, robust regression model with the least trimmed squares estimation method was used to evaluate associations between IL-6 levels and area change and between IL-6 and flow change [18] . Statistical significance was defined as a two-tailed P value less than 0.05, and data are presented as means. A power calculation indicated that 42 patients in each group (HIVþCADÀ and HIVÀCADÀ) were needed to detect a conservative absolute difference of 3% in stress-induced CSA between HIVþCADÀ and HIVÀCADÀ patients (SD ¼ 6% for each group for %CSA). However, after an interim analysis, we observed greater CEF differences between groups than originally anticipated that were highly statistically significant and no additional patients were enrolled.
Results
Patient characteristics
The characteristics of all study patients are presented in Table 1 . Note that $95% of HIVþ patients were taking ARTwith suppression of HIV RNA level (88% with HIV RNA < 20 copies/ml) and CD4 þ cell counts more than 200 cell/ml (Table 1) . Importantly, there was no significant difference in age, BMI, diabetes, tobacco abuse, or cardiovascular medication use between the HIVþCADÀ and risk-factor-matched HIVÀCADÀ participants ( Table 1 ). The prevalence of hypertension trended nonsignificantly higher in the HIVþCADÀ patients than in HIVÀCADÀ patients (P ¼ 0.09). All patients completed the MRI-IHE study, and there were no significant differences in mean RPP change or peak RPP during IHE among the four groups. Representative MR images, including those demonstrating changes in CSA and CBF during IHE, are shown in Fig. 1 .
Coronary endothelial function in healthy patients and coronary artery disease patients (HIVS) HIVÀCADÀ patients exhibited coronary vasodilatation during IHE (þ10.2 AE 0.9% CSA change with IHE P < 0.0001 vs. baseline) whereas HIVÀCADþ exhibited no significant change in CSA during IHE (À0.6 AE 1.7% CSA change from baseline, P ¼ NS) (Fig. 2) . Likewise, there was a significant increase in mean CBF (þ41.2 AE 5.1%) in HIVÀCADÀ patients with IHE but no change in the HIVÀCADþ group (þ3.4 AE 4.2% CBF change, P ¼ NS) (Fig. 3) . These observations are consistent with prior studies [10, 14] .
Coronary endothelial function in HIV-positive patients without coronary artery disease To determine whether CEF is impaired in HIVþ individuals early, in the absence of CAD, we compared CEF in HIVþCADÀ individuals with that of HIVÀCADÀ. Coronary arteries in HIVþCADÀ patients minimally vasodilated with IHE (þ3.2 AE 1.2% mean CSA change with IHE P ¼ NS vs. baseline), and the degree of vasodilation with IHE was significantly impaired as compared with that of HIVÀCADÀ (þ10.2 AE 0.9% mean CSA change with IHE, P < 0.0001, Fig. 2a) . The abnormal CSA response of HIVþCADÀ patients was not significantly different than that of the HIVÀCADþ patients (À0.6 AE 1.7% CSA change from baseline P ¼ NS, Fig. 2a ). There was no significant increase in CBF during IHE in HIVþCADÀ patients. The CBF response of HIVþCADÀ patients (þ6.2 AE 3.0% CBF change from baseline) was significantly less than that of controls (þ41.2 AE 5.1% CBF increase from baseline, P < 0.0001), but not different than that of patients with clinical CAD (þ3.4 AE 4.2% CBF change, P ¼ NS, Fig. 2b ).
To determine whether the significant coronary endothelial dysfunction observed in the HIVþ CADÀ patients were related to coinfection with HCV, we performed additional analyses on the subset of HIVþCADÀ patients who were HCVÀ (n ¼ 11) and on the subset of HIVþCADÀ patients who were either HCVÀor who were HCV treated and cured (total n ¼ 15). The mean change in %CSA and CBF in these two groups (HIVþCADÀHCVÀ and HIVþCADþHCVc, Supplemental Figs. 1-4 http:// links.lww.com/QAD/B72) was similar to that of the overall HIVþCADÀ patients (Main Fig. 2 ) and significantly depressed compared with that of the healthy patients. Thus, the significantly depressed CEF observed in HIVþCADÀ patients was not attributable to concurrent HCV infection.
On multivariate analysis when data were adjusted for age, BMI, sex, race, hypertension, and active hepatitis C infection, the IHE-induced changes in CSA (P ¼ 0.01) and in CBF (P < 0.001) were still significantly reduced in HIVþCADÀ patients as compared with those of HIVÀCADÀ patients. Thus, HIVþ patients with no significant CAD have severely impaired CEF that is similar to that of HIVÀ patients with established CAD. P ¼ NS). Likewise, CBF did not change significantly with IHE in either HIVþCADþ patients (þ3.6 AE 3.5% CSA change from baseline, P ¼ NS) or HIVÀCADþ patients (þ3.4 AE 4.2% CSA change from baseline, P ¼ NS; Fig. 2 ). Thus, although CEF was significantly impaired in HIVþ people before the development of CAD (HIVþCADÀ vs. HIVÀCADÀ), CEF does not seem to be further impaired in HIVþ people with CAD as compared with that in HIVÀ people with clinical CAD.
Inflammatory parameters and coronary endothelial function
To determine whether the extent of CEF impairment in HIVþ participants is related to systemic inflammation, hsCRP, and IL-6 were measured and compared with each CEF parameter. Although mean hsCRP levels did not differ among the four groups (Fig. 3a) , IL-6 levels did significantly differ (P < 0.001) with significantly higher levels in HIVþCADÀ than in HIVÀCADÀ individuals (P < 0.001) (Fig. 3b) . IL-6 levels were not different between HIVÀCADÀ and HIVÀCADþ individuals (Fig. 3b) . Importantly, IL-6 levels in HIVþ individuals were significantly inversely related to CEF, as measured by mean %CSA and CBF changes with IHE (Fig. 4) . The correlation was still significant after correction with a robust regression analysis in consideration of possible influential data (P ¼ 0.007 for IL-6 vs. %CSA and P ¼ 0.03 for IL-6 vs. %CBF). However, when removing the three outliers from the 27 patients this correlation became nonsignificant.
Discussion
This study demonstrates that HIVþ participants, even in the absence of overt CAD and coronary artery calcification, have significant coronary endothelial dysfunction that is as severe as that in HIVÀ patients with established clinical CAD. Although HIVþ participants with CAD exhibit severely depressed CEF, as expected, it is not more severely depressed than that in CAD patients who are HIVÀ. The depressed CEF in HIVþ patients may be related to an augmented inflammatory pattern, as measured by IL-6, despite chronically suppressed HIV RNA levels and sufficient CD4 þ cell counts (Table 1) .
HIV and coronary endothelial dysfunction Iantorno et al. 1285 Coronary endothelial function in HIV-negative healthy patients and coronary artery disease patients Coronary endothelial dysfunction is a well known independent predictor of cardiovascular events, and a potential target for medical interventions in HIVÀpopulations [3] . We used a noninvasive, reproducible MRI method to measure NO-mediated CEF [9, 10, 17] that allow studies in healthy and low-risk populations and for repeated studies unlike prior catheterization-based measures. In the current study, healthy patients without HIV infection (HIVÀCADÀ) exhibited coronary vasodilatation and an increase in CBF during IHE, whereas patients with CAD (HIVÀCADþ) exhibited no significant change in CSA and CBF during IHE, consistent with prior studies [10, 14] .
AIDS 2017, Vol 31 No 9
Fig . 2 . (a) Summary coronary endothelial function results for mean cross-sectional area change in response to isometric handgrip exercise for healthy patients (HIVSCADS; black bar, n U 36), HIVRCADS patients (striped bar, n U 18), patients with CAD (HIVSCADR; white bar, n U 41), and patients with HIV and CAD (HIVRCADR, diamond bar, n U 17). Data are shown on a per patient basis. ANOVA was used for among group comparisons (P < 0.0001, data normally distributed). Ã P < 0.0001 vs. HIVÀCADÀ group. C P < 0.001 vs. HIVþCADþ. (b) Summary coronary endothelial function results for the coronary blood flow responses to isometric handgrip exercise for healthy patients (HIVÀCADÀ; black bar, n ¼ 36), HIVþCADÀ patients (striped bar, n ¼ 18), participants with CAD (HIVÀCADþ; white bar, n ¼ 41), and participants with HIV and CAD (HIVþCADþ, diamond bar, n ¼ 17). Data are shown on a per patient basis. Kruskal-Wallis test was used for among group comparisons (P < 0.0001, data not normally distributed). Ã P < 0.0001 vs. HIVÀCADÀ group. Kruskal-Wallis test was used for among group comparisons (P < 0.001, data not normally distributed). Ã P < 0.001 vs. HIVÀCADÀ group; y P < 0.05 vs. HIVÀCADÀ group.
Coronary endothelial function in HIV-positive patients without overt coronary artery disease To our knowledge, this is the first study to demonstrate that HIVþ individuals on contemporary suppressive ART and no significant coronary atherosclerosis have profoundly worse CEF compared with a matched HIVÀ population (Figs. 2-3 ). Although prior studies reported the presence of peripheral endothelial dysfunction in HIVþ populations [19, 20] , peripheral artery endothelial function correlates only modestly with CEF [8] , and the latter is more closely related to underlying local CAD [3] . Myocardial perfusion in HIVþ patients was evaluated with PET in two prior studies but neither demonstrated abnormal CEF. One study using dipyridamole stress that induces maximal vasodilatation but is not purely an endothelial-dependent stressor, reported no difference between HIVþ patients and a control group [21] . Another PET study measured myocardial perfusion in HIVþ people during cold pressor testing, an arguably more endothelial-dependent stressor than dipyridamole, but the study had no HIVÀ patients for comparison [22] and the cold pressor perfusion results in HIVþ patients were similar to those previously reported in healthy patients [23] . The MRI techniques used here offer direct measures of coronary artery area and blood flow changes in response to a demonstrated NO-dependent endothelial stressor [9] .
The presence of coronary endothelial dysfunction observed here in HIVþ people may explain in part why HIVþ individuals are at increased risk for cardiovascular events despite a suppressed HIV RNA level [24] , even in the absence of overt coronary atherosclerosis. In HIVÀpopulations, abnormal CEF is associated with an approximately two-fold increased risk of cardiovascular events [3] . Likewise, the relative risk of cardiovascular events is increased a similar amount ($1.75) in HIVþ compared with an HIVÀ matched population [2] . Therefore, this degree of observed coronary endothelial dysfunction in HIVþ patients is sufficiently large, in theory, to account for much of the increased cardiovascular risk in this population. All of our HIVþCADÀ study participants previously underwent imaging studies that indicated no calcified CAD and most (83%) underwent angiography, all demonstrating no stenosis. Thus, these findings demonstrate that coronary endothelial dysfunction is present even in the absence of luminal stenosis and calcified coronaries, and raise the question of whether further risk characterization may be needed in the HIVþ population.
To determine the degree of coronary endothelial dysfunction in HIVþ participants with clinical CAD, we compared CEF in HIVþCADþ individuals with that of CAD patients who were HIVÀ. The HIVþCADþ patients significantly vasoconstricted in response to IHE, and the degree of their endothelial dysfunction did not significantly differ from that of the HIVÀCADþ patients. These findings are notable in light of the fact that the HIVþ group was medically optimized with ART with a fully suppressed HIV RNA and suggests that once clinical CAD develops, CEF does not significantly further worsen with HIV infection.
Correlation between inflammatory parameters and coronary endothelial dysfunction Increased systemic inflammation has been implicated in the pathogenesis of cardiovascular disease in HIVþ patients [12] . Although hsCRP did not significantly differ among the groups, IL-6 was significantly increased in HIVþCADÀ compared with HIV-CADÀ patients. Moreover, there was an inverse relationship between IL-6 and CEF, indicating that an increased level of inflammation as measured by IL-6 is associated with impaired CEF. Prior studies report that plasma levels of proinflammatory cytokines including IL-6 are increased in HIVþ individuals [25, 26] and persist during HIV infection, even in patients with low residual viremia (viral load 20 copies/ml) [27, 28] . Higher levels of IL-6 strongly predict cardiovascular events in ART-treated and ART-naive HIVþ patients [29, 30] . Interestingly, IL-6 is reported to be more predictive of adverse cardiovascular HIV and coronary endothelial dysfunction Iantorno et al. 1287 events than the inflammatory marker hsCRP in HIVþ patients [13, 30] . Of note, in our study when removing from this analysis the three potential outliers, the correlation was no longer significant (R ¼ À0.27). A larger study could better determine whether the observed relationship between inflammation and endothelial dysfunction in HIVþ people is robust.
Limitations This is a cross-sectional study, and thus it is difficult to determine whether the significant abnormalities in CEF observed in HIVþ participants on contemporary therapy are due to HIV infection, ART, or something else. It should be emphasized, however, that the groups were well matched in terms of age, tobacco use, hypertension and diabetes. In addition, on multivariate analysis, none of the known confounders including HTN and HCV status accounted for the differences in CEF between the HIVþ and the control groups. Although we noted that the HIVþCADÀ group had endothelial dysfunction to a degree similar to that of the HIVÀ patients with known CAD, most of the CAD patients were on statin therapy which may have attenuated the decline in CEF that would otherwise have been observed in the CAD group. Regardless, the main observation of this study is that CEF is significantly impaired in HIVþCADÀ patients as compared with HIVÀCADÀ patients, and these two groups are well matched in terms of conventional cardiovascular medications and risk factors. The sample size may not afford sufficient power to detect a modest correlation between hsCRP levels and endothelial dysfunction. However, the sample size was sufficient to detect an inverse relationship between IL-6 and CEF in HIVþ participants. The latter relationship may be influenced by a few patients and merits additional studies in larger populations. Another limitation is that the MRI analysis was not performed blinded in terms of HIV status. However, in a subset of HIVÀCADÀ and HIVþCADÀ patients, repeated blinded analysis yielded similar results (data not shown). Other markers, such as ones of monocyte activation sCD163 or sCD14 have not been tested in our study population and have been associated with endothelial dysfunction and CAD risk factors in other studies [31] . Likewise, additional studies would be required to determine whether other factors such as HIV duration, immune factors, or type of ART may affect CEF and cardiovascular risk.
Conclusion
In summary, coronary endothelial dysfunction is present in HIVþ people with no overt CAD, and the degree of dysfunction is similar to that of patients with established clinical CAD. The mechanism of endothelial dysfunction may be partly related to increased systemic inflammation even in the presence of adequately treated HIV infection. Our findings suggest the possibility that noninvasive measurement of CEF with MRI may complement risk assessment in HIVþ patients even in the absence of significant CAD and may provide a valuable tool to probe new treatment approaches aimed at targeting the earliest stages of coronary disease in HIVþ populations.
